Business · 26/05/2023
FDA Releases Final Guidance on Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products
The US Food and Drug Administration (FDA) has released a final guidance document to help pharmaceutical companies adjust for covariates in clinical trials for drugs and biological products, finalizing recommendations made in a 2021 draft.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →